



Our Platform

SkySTAR Skyhawk Small molecule Therapeutics for Alternative splicing RNA

THE CHALLENGE

RNA mis-splicing leading to loss of RNA expression has been found to cause a growing list of diseases, from orphan and neurological conditions to major cancers. Very few treatments are available for these challenging conditions, many of which have been considered "undruggable."




THE OPPORTUNITY

Skyhawk's novel approach corrects the underlying genetics of disease at the mRNA level, in the nucleus of the cell. Our drugs can target major neurological conditions, targets previously considered undruggable, such as master transcriptional factors in cancer and a host of targets in immunology, inflammation and infectious diseases.




Skyhawk small molecules





OUR PLATFORM



Our SkySTAR* (Skyhawk Small molecule Therapeutics for Alternative splicing in RNA) platform integrates information from computational, kinetic, & structural models of RNA



Generating unique and selective families of chemistry for each target



Our focused libraries are then tested in patient cells using proprietary assays, to quickly yield potent drug candidates




OUR PIPELINE


Our current pipeline includes oncology and neurology targets.




Skyhawk Neuro Target 1



Skyhawk Neuro Target 2



Skyhawk Neuro Target 3



HOME

Skyhawk Therapeutics, Inc.

Skyhawk Therapeutics Europe GmbH



35 Gatehouse Drive

Basel Technology Park

SCIENCE

Waltham, MA 02451

Hochbergerstrasse 60C



United States of America

Basel 4057

ABOUT

info@skyhawktx.com

Switzerland

Tel: 617.858.0041

swiss-info@skyhawktx.com

NEWS

Tel: +41 (0) 61 638 23 50

CONTACT

CAREERS

Copyright 2019 SKYHAWK THERAPEUTICS, INC.
SKYHAWK® and SKYSTAR® are registered trademarks of Skyhawk Therapeutics, Inc. in the US and other countries.